U.S., Jan. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07326215) titled 'A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+' on Dec. 09, 2025.
Brief Summary: PrismaLung+ is a sterile, single-use medical device aimed at performing partial removal of carbon dioxide (CO2) from the patient's venous blood via diffusion through a membrane. The goal of this prospective, open label, randomized controlled study is to evaluate the efficacy and safety of PrismaLung+ on extracorporeal carbon dioxide removal (ECCO2R) in critically ill patients under invasive mechanical ventilation (IMV). Patients will be randomized to receive either IMV combined with ECCO2R (using PrismaLung+...